Elsevier

Cellular Immunology

Volume 179, Issue 2, 1 August 1997, Pages 174-184
Cellular Immunology

Regular Article
FLT3 Ligand Induces the Generation of Functionally Active Dendritic Cells in Mice

https://doi.org/10.1006/cimm.1997.1152Get rights and content

Abstract

FLT3 ligand (FL) is a recently described hematopoietic growth factor that stimulates the proliferation and differentiation of hematopoietic progenitors. We have investigated the effect of FL on murine hematopoiesis and dendritic cell (DC) generation and accumulation in lymphoid tissues and liverin vivoandin vitroevaluating the morphologic, phenotypic, and functional characteristics of these DC. We have observed extramedullary hematopoiesis in the mouse spleen with all lineages of hematopoietic cells represented after the administration of FL. Injection of FL results in a time-dependent and reversible accumulation of DC in the spleen, bone marrow, lymph nodes, and liver. Both flow cytometry and immunohistochemistry revealed a significant accumulation of DC in these tissues. Results of mixed leukocyte reaction suggested that these cells, isolated from murine bone marrow or spleen, were active as antigen presenting cells. Furthermore, cultivation of splenic and marrow cells with GM-CSF and IL-4 gave rise to large numbers of functionally active mature DC. Thus, the results of this study suggest that FL is a promising growth factor that stimulates the generation of large number of DC and may be a useful cytokine for the immunotherapy of cancer.

References (63)

  • F. Agnes et al.

    Gene

    (1994)
  • C. Sherr

    Blood

    (1990)
  • W. Matthews et al.

    Cell

    (1991)
  • O. Rosnet et al.

    Genomics

    (1991)
  • K. Tsuji et al.

    Blood

    (1991)
  • S.D. Lyman et al.

    Cell

    (1993)
  • S.D. Lyman et al.

    Blood

    (1994)
  • F.C. Zeigler et al.

    Blood

    (1994)
  • A. Galy et al.

    Immunity

    (1995)
  • A. Shah et al.

    Blood

    (1996)
  • H.J. McKenna et al.

    Blood

    (1995)
  • M. Gabbianelli et al.

    Blood

    (1995)
  • M.O. Muench et al.

    Blood

    (1995)
  • S. Hudak et al.

    Blood

    (1995)
  • K. Brasel et al.

    Blood

    (1996)
  • R.M. Steinman

    Annu. Rev. Immunol.

    (1991)
  • M.R. Shurin

    Cancer Immunol. Immunother.

    (1996)
  • P. Matzinger et al.

    Nature

    (1989)
  • K. Shortman et al.

    Dendritic Cells in Fundamental and Clinical Immunology

    (1995)
  • R. Thomas et al.

    Stem Cells

    (1996)
  • R. Agger et al.

    Int. Rev. Immunol.

    (1990)
  • P. Szabolcs et al.

    J. Immunol.

    (1995)
  • J.M. Austyn

    In Vivo

    (1993)
  • K. Inaba et al.

    J. Exp. Med.

    (1992)
  • C. Caux et al.

    Nature

    (1992)
  • F. Sallusto et al.

    J. Exp. Med.

    (1994)
  • E. Maraskovsky et al.

    J. Exp. Med.

    (1996)
  • S.D. Lyman

    Int. J. Hematol.

    (1995)
  • H.J. McKenna et al.

    Bone Marrow Transplantation

    (1996)
  • M. R. Shurin, P. P. Panharipande, M. L. Lotze, Israel J. Med....
  • D. Small et al.

    Proc. Natl. Acad. Sci. USA

    (1994)
  • Cited by (181)

    • Dendritic cell-based cancer immunotherapy: The stagnant approach and a theoretical solution

      2014, Drug Discovery Today
      Citation Excerpt :

      Further details of the suggested protocols can be found in Supplemental material online. The choice of the above model is based on the ability of the liver to recruit and propagate DC [38,39,41], and the high density of resident DC [25]. Mouse models of liver tumors are also beneficial because hepatic artery delivery enables sufficient liver tumor targeting [42].

    • Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity

      2012, Biochimica et Biophysica Acta - Reviews on Cancer
    View all citing articles on Scopus
    View full text